Opinion|Videos|July 17, 2024
Infection Risk Management Counseling For Patients Receiving Treatment for PNH
Key discussion points for educating patients on infection risk management in PNH care are highlighted.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Given the increased risk of serious infections with encapsulated bacteria associated with complement inhibitor therapy, what strategies do you employ to effectively counsel patients on infection risk mitigation strategies, such as vaccinations and antibiotic prophylaxis?
Advertisement
Related to this article
ASCOLT finds no overall adjuvant aspirin benefit in colorectal cancer, but meta-analysis links improved disease-free survival to PIK3CA exon 9/20 mutations.
Real-world DLBCL data show Incyte’s tafasitamab matches L-MIND responses across diverse Non-Hodgkin lymphoma patients, per Cardinal Health review.
Francesca Polverino, MD, PhD, discusses COPD biomarkers, patient susceptibility, overtreatment risk, and the future of risk stratification.
An independent review of BTK inhibitors in mantle cell lymphoma finds areas are of strength both second-generation therapies, as authors call for clinical trials to inform guidelines.
Five August FDA approvals introduced novel therapies across vaccines, neurology, oncology, myeloma, and dermatomyositis, despite some regulatory pushback.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
A Patient-Centered Reconstruction of 340B in Oncology: Transparency, Equity, and Site-of-Care Accountability
3
Aspirin's CRC Benefit Narrows to PIK3CA Exon 9/20 Mutations
4
Designing Effective Value-Based Oncology Models: Lalan Wilfong, MD
5